Related Experiment Video
Updated: Aug 5, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Evidence-Based Cardiovascular-Kidney-Metabolic Therapies in Kidney Transplant Recipients
Gautam R Shroff1, Xingxing Cheng2, Ara Gharabagi3
1Division of Cardiology, Department of Medicine, Hennepin Healthcare; and University of Minnesota Medical School, Minneapolis, MN.
Abstract:
Pivotal clinical trials have heralded several new classes of pharmacological agents focused on improving combined heart-kidney outcomes among patients with cardiovascular-kidney-metabolic syndrome. This review compiles the current evidence pertaining to the use of these novel, exciting classes of agents among kidney transplant recipients. Treatment with renin-angiotensin-aldosterone system inhibitors continues to remain the backbone of pharmacological management among kidney transplant recipients for several indications. Data from systematic reviews and meta-analyses support the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists with several comorbidities. However, evidence for both nonsteroidal and steroidal mineralocorticoid receptor antagonists and angiotensin receptor-neprilysin inhibitors is emerging and not adequate to support routine clinical use in kidney transplant recipients. Finally, data from randomized controlled trials on statins serve as a reminder of their impact in the metabolic milieu following kidney transplantation. Using the recently introduced paradigm of cardiovascular-kidney-metabolic syndrome, this review proposes that four pharmacological agents constitute the key pillars for improving downstream heart-kidney outcomes based on existing evidence - renin-angiotensin-aldosterone system inhibitors, statins, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Furthermore, this review highlights relevant practical drug interactions with immunosuppressants and considerations of tolerability of these agents among kidney transplant recipients. Finally, this review discusses specific management considerations for coronary heart disease, heart failure and atrial fibrillation with unique nuances applicable to kidney transplant recipients. There remains a critical need for randomized trials in this vulnerable population focused on improvement in combined heart-kidney outcomes.
Insights
New heart-kidney medications show promise for kidney transplant patients with cardiovascular-kidney-metabolic syndrome. Renin-angiotensin-aldosterone system inhibitors and statins are key, with emerging data for SGLT2 inhibitors and GLP-1 RAs.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Cardiovascular-kidney-metabolic (CKM) syndrome impacts kidney transplant recipients (KTRs).
- Novel pharmacological agents are being developed to improve combined heart-kidney outcomes in CKM syndrome.
- Evidence for these agents in KTRs is evolving.
Purpose of the Study:
- To review current evidence on novel pharmacological agents for KTRs with CKM syndrome.
- To identify key drug classes for improving heart-kidney outcomes in KTRs.
- To discuss drug interactions, tolerability, and specific cardiovascular conditions in KTRs.
Main Methods:
- Systematic review of pivotal clinical trials and meta-analyses.
- Analysis of evidence for renin-angiotensin-aldosterone system inhibitors, SGLT2 inhibitors, GLP-1 RAs, MRAs, ARNIs, and statins.
- Consideration of drug interactions with immunosuppressants and tolerability.
Main Results:
- Renin-angiotensin-aldosterone system inhibitors remain foundational.
- Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists show support for use in KTRs with comorbidities.
- Evidence for mineralocorticoid receptor antagonists and angiotensin receptor-neprilysin inhibitors is insufficient for routine use.
- Statins demonstrate impact on the post-transplant metabolic milieu.
Conclusions:
- Four key pillars for improving heart-kidney outcomes in KTRs: RAAS inhibitors, statins, SGLT2 inhibitors, and GLP-1 RAs.
- Practical considerations include drug interactions and tolerability.
- Further randomized trials are needed to confirm benefits in this vulnerable population.
More Related Videos
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
